Shares of Danish pharmaceutical Lundbeck lost 7.2% on Friday morning after the company said that phase III trials of its stroke drug desmoteplase did not meet a primary endpoint. "These data are surprising and are not consistent with previously observed patterns," said the company.
It's planning to undertake more analysis on the data. Lundbeck licenced Desmoteplase from Paion . Forest Laboratories holds the marketing rights to the drug in the U.S. and Canada. Paion shares were down 60.2% in Germany.
Source
No comments:
Post a Comment